The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
M ComaschiCOM06 Study Investigators


Diabetic dyslipidaemia contributes to the increased risk of cardiovascular disease in patients with Type 2 diabetes. This paper examines the effectiveness of adding pioglitazone to metformin or a sulphonylurea (SU) compared with a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia in patients with Type 2 diabetes. Patients (n=250) treated with metformin (< or =3g/day) or an SU as monotherapy at a stable dose for > or =3 months were randomised to receive either pioglitazone (15-30 mg/day) in addition to their metformin or SU, or a fixed-dose combination tablet containing metformin (400mg) and glibenclamide (2.5 mg) [up to 3 tablets daily] for 6 months. Addition of pioglitazone tended to increase plasma high-density lipoprotein-cholesterol (HDL-C) [0.04 mmol/L; P=0.051] at 6 months and significantly reduced plasma triglycerides (-0.25 mmol/L; P=0.013) compared with baseline. Patients treated with metformin/glibenclamide for 6 months had reduced HDL-C (-0.09 mmol/L; P<0.01) and no change in plasma triglyceride levels (0.03 mmol/L; P=0.733). Both treatment regimes resulted in a similar level of glycaemic control. The beneficial effects of pioglitazone on diabetic dyslipidaemia may help combat the increa...Continue Reading


Aug 9, 2001·Coronary Artery Disease·S RosenblattPioglitazone 026 Study Group
Oct 9, 2002·Current Medical Research and Opinion·Melanie J Davies
Oct 27, 2004·Archives of Internal Medicine·Elaine ChiquetteR A DeFronzo
Dec 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Guntram SchernthanerQuartet [corrected] Study Group
Mar 25, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·Bernard CharbonnelQUARTET Study Group
Jun 21, 2005·Journal of the American College of Cardiology·Andreas PfütznerThomas Forst
Dec 24, 2005·Diabetes Care·American Diabetes Association
Jun 21, 2006·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Paulos BerhanuPenny R Fleck
Oct 17, 2006·Drugs·Emma D Deeks, Lesley J Scott

Related Concepts

Pioglitazone hydrochloride
Blood Glucose
Diabetes Mellitus, Non-Insulin-Dependent
Drug Combinations
Hypoglycemic Effect
High Density Lipoprotein Cholesterol
Cholesteryl Linoleate, LDL

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.